Sex organ

Insights on the Reiter's Syndrome Treatment Global Market to 2027 - Rapidly Increasing Reactive Arthritis Incidences and Rising Demand for Effective Treatment are Expected to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health, General Health, Chlamydia trachomatis, Adult, Reactive arthritis, Inflammation, Sex, Salmonella, Sex organ, Arthritis, Campylobacter, Diarrhea, Administration, Population, Health, Growth, Market share, Syndrome, Genetically modified bacteria, Patient, CDC, Dosage form, Bacteria, Arthralgia, Inflammatory arthritis, Method, Ageing, Disease, Route of administration, CAGR, Birth control, Shigella, Yersinia

The global Reiter's syndrome treatment market is anticipated to grow at a significant CAGR during the forecast period, 2023-2027.

Key Points: 
  • The global Reiter's syndrome treatment market is anticipated to grow at a significant CAGR during the forecast period, 2023-2027.
  • The market growth can be attributed to the rising instances of reactive arthritis and advancements in treatment processes and methods.
  • Besides, advances in the healthcare industry have led to better accessibility of patient care suffering from severe conditions like reactive arthritis, contributing to the growth of the global Reiter's syndrome treatment market.
  • Rapidly increasing reactive arthritis incidences and rising demand for effective treatment are expected to drive the global Reiter's syndrome treatment market over the next five years.

Global Genital Herpes Treatment Market Outlook Report 2022-2027 Featuring Key Vendors - GlaxoSmithKline, Glenmark Pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, & Bausch Health Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Infectious Diseases, Pharmaceutical, Health, People, FDA, LGBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, Ageing, Valaciclovir, Pharmacy, Retail, Risk, MSM, Famciclovir, Recurrence, Sex organ, Food, Simplex, Population, NE, Geography, GSK, Incidence, IND, Man, HSV, Patient, HSV-2, Company, Genital herpes, Vaccine, STD, OTC, Infection, Awareness, Immunodeficiency, Sanofi, Herpes labialis, WHO, Technology, Herpes simplex virus, HIV, Factor X, Sex, STI, Vertically transmitted infection, Investigational New Drug, Pharmaceutical industry, Birth control, Aciclovir, Aciclovir, Pritelivir, Moderna

The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
  • HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes.
  • North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%.

Genital Herpes Pipeline Insight Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Herpes simplex virus, DNA, II, Infection, News, Sex organ, HSV, Mergers and acquisitions, Clinical trial, Half-life, Cell, Virus, Therapy, Genital herpes, Discovery, Plasma protein binding, Pritelivir, Immunoglobulin G, Pharmaceutical industry, Vaccine, Beef cattle

The "Genital Herpes - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Genital Herpes- Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Genital Herpes pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D.
  • This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.